S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:TSHA

Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

$2.27
-0.14 (-5.81%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$2.14
$2.43
50-Day Range
$1.46
$3.25
52-Week Range
$0.50
$3.89
Volume
1.79 million shs
Average Volume
2.66 million shs
Market Capitalization
$424.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.88

Taysha Gene Therapies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
202.9% Upside
$6.88 Price Target
Short Interest
Bearish
9.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of Taysha Gene Therapies in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.39) to ($0.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.27 out of 5 stars

Medical Sector

498th out of 907 stocks

Biological Products, Except Diagnostic Industry

76th out of 148 stocks

TSHA stock logo

About Taysha Gene Therapies Stock (NASDAQ:TSHA)

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

TSHA Stock Price History

TSHA Stock News Headlines

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 7.5%
Taysha Gene Therapies (NASDAQ:TSHA) Trading 3% Higher
Impact and Outlook: Taysha Gene Therapies Stock Analysis
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Taysha Gene Therapies: Q4 Earnings Insights
See More Headlines
Receive TSHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TSHA
Fax
N/A
Employees
52
Year Founded
2020

Price Target and Rating

Average Stock Price Target
$6.88
High Stock Price Target
$9.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+202.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-111,570,000.00
Net Margins
-722.06%
Pretax Margin
-722.06%

Debt

Sales & Book Value

Annual Sales
$15.45 million
Book Value
$0.40 per share

Miscellaneous

Free Float
182,810,000
Market Cap
$424.53 million
Optionable
Optionable
Beta
0.29

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Sean P. NolanMr. Sean P. Nolan (Age 56)
    CEO & Chairman
    Comp: $674k
  • Dr. Sukumar Nagendran M.D. (Age 57)
    President, Head of Research & Development and Director
    Comp: $619.1k
  • Mr. Kamran Alam CPAMr. Kamran Alam CPA (Age 46)
    M.B.A., CFO & Corporate Secretary
    Comp: $703.61k
  • Hayleigh Collins
    Director & Head of Corporate Communications
  • Ms. Tracy M. Porter SPHR
    Chief People Officer
  • Mr. Frederick Porter Ph.D.
    Chief of Staff & Technical Operations Officer
  • Ms. Emily McGinnis M.P.H.
    Chief Patient Advocacy & External Affairs Officer
  • Mr. Sean McAuliffe
    Chief Business Officer
  • Dr. Steven Gray Ph.D.
    Chief Scientific Advisor of UT Southwestern Gene Therapy Program
  • Berge Minassian M.D.
    Chief Medical Advisor of UT Southwestern Gene Therapy Program

TSHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Taysha Gene Therapies stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TSHA shares.
View TSHA analyst ratings
or view top-rated stocks.

What is Taysha Gene Therapies' stock price target for 2024?

8 Wall Street research analysts have issued 1-year price objectives for Taysha Gene Therapies' shares. Their TSHA share price targets range from $5.00 to $9.00. On average, they predict the company's share price to reach $6.88 in the next year. This suggests a possible upside of 202.9% from the stock's current price.
View analysts price targets for TSHA
or view top-rated stocks among Wall Street analysts.

How have TSHA shares performed in 2024?

Taysha Gene Therapies' stock was trading at $1.77 on January 1st, 2024. Since then, TSHA stock has increased by 28.2% and is now trading at $2.27.
View the best growth stocks for 2024 here
.

When is Taysha Gene Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TSHA earnings forecast
.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its quarterly earnings results on Tuesday, March, 19th. The company reported $0.35 EPS for the quarter. The company earned $3.60 million during the quarter, compared to the consensus estimate of $4.75 million.

When did Taysha Gene Therapies IPO?

Taysha Gene Therapies (TSHA) raised $125 million in an initial public offering on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager.

Who are Taysha Gene Therapies' major shareholders?

Taysha Gene Therapies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.01%). Insiders that own company stock include John A Stalfort III, Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad.
View institutional ownership trends
.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TSHA) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners